Francesco DeRubertis

venture capitalist @medicxi

[JonnyFinlay @Finlay_Jonny]

Huge thanks to the great people from @medicxi for founding and getting us here. Double thanks to @fderubertis and @Kevinjohnson360 for the vision to help found it in the first place.

[Medicxi @medicxi]

We are excited to announce the launch of Ottimo Pharma, with the appointment of David Epstein as Chair & Chief Executive Officer. He is joined by Mehdi Shahidi, Head of Development & Chief Medical Officer, and James Sabry as Vice Chair of the Board

https://t.co/clThF0KOf0

[Medicxi @medicxi]

Exciting news for our portfolio company Vaderis who announced positive results from its randomized, double-blind, placebo-controlled Proof-of-Concept clinical trial in patients suffering from Hereditary Haemorrhagic Telangiectasia (HHT)

[Medicxi @medicxi]

This could be a transformative outcome for patients living with #osteoarthritis, where currently available analgesics are limited by adverse events, addiction liabilities and poor efficacy

[Medicxi @medicxi]

Congratulations to @MedicxiKevin and the Levicept team for these positive Phase 2 results for LEVI-04 in #osteoarthritis:

https://t.co/gjYWlEvFJs

[Medicxi @medicxi]

In this global multi-centre Phase 2 study of >500 participants, LEVI-04 met all primary and secondary efficacy endpoints with significant analgesia across all measures for all doses vs placebo

LEVI-04 was well tolerated, and detailed examination found no increased incidence of rapidly progressive osteoarthritis

[Rivus Pharmaceuticals @RivusPharma]

Our CEO, Dr. Jayson Dallas, shares with @PharmaVoice how our unique therapeutic approach is focused on metabolic rate, not just weight loss, and has the potential to redefine the treatment landscape for #CardiometabolicDiseases. Read more: https://t.co/9ISP4jInPX

[Mount Sinai Dermatology @MSHSDerm]

Itch Session: Updates in the pathophysiology of #Itch presented by @itchdoctor
The sensory paradigm of cytokines/JAK signaling, neuro-immune interface, & more at #AAD2024 #SanDiego @EmmaGuttman @IcahnMountSinai

[Brian S. Kim @itchdoctor]

Please join us today at the Dermatology Innovation Forum where I will introduce Alys Pharmaceuticals, a transformative immuno-dermatology innovation engine that I helped to co-found with many others including @HarrisVitiligo @Finlay_Jonny. #skin #itch #vitiligo #alopecia #dermatitis #urticaria
https://t.co/xcgTbO35ab

[Medicxi @medicxi]

We created Levicept with cofounder Simon Westbrook as a @medicxi newco in 2012. Under a leadership team spearheaded by Eliot and Simon as CSO, we strongly believe that LEVI-04 can effectively target the clinically proven neurotrophin pain pathways with a superior safety profile.

[Medicxi @medicxi]

Delighted to welcome @EliotForster as CEO of Levicept. We look forward to working with you on the ongoing phase II studies for Levi-04, our once-a-month injectable for the treatment of osteoarthritis and chronic pain.

More details here: https://t.co/eXUdCRqxiW

[Medicxi @medicxi]

Over the next three years, Alys aims to deliver several clinical proof-of-concept readouts and advance at least one program to registrational studies.

[Medicxi @medicxi]

The Alys leadership team strongly believe that underserved disease areas, such as atopic dermatitis, vitiligo, alopecia areata and chronic spontaneous urticaria, will see the next breakthroughs in dermatological advancements.

[Medicxi @medicxi]

We’re proud to announce the launch of Alys Pharma, an immuno-dermatology focused company backed with $100m financing by @medicxi and led by world leading scientific experts dedicated to developing transformative medicines for dermatology patients worldwide https://t.co/q1Rh1HZC3d

[Francesco DeRubertis @fderubertis]

@MathsNotebook @pronuncemistak 10

[John E. Harris, MD, PhD @HarrisVitiligo]

A few thoughts about my experience as an academic dermatologist and serial entrepreneur. . .

https://t.co/6EtMMlaGL1

[OptimumComms @OptimumComms]

@Medicxi has today launched its $400m Medicxi IV fund.

The new fund will continue to support drug hunters with clear product visions to deliver transformative #therapies for #patients

Read more about the fund here: https://t.co/zLSrNsIucq

#Medicxi #MedicxiIV

[Medicxi @medicxi]

Congrats to @medicxi portfolio company @VersanisBio on its acquisition by @EliLillyandCo
https://t.co/OauDE0dpKX

[Medicxi @medicxi]

Huge strides have been made in the therapeutic management of obesity. @VersanisBio bimagrumab reduces fat mass whilst at the same time increasing muscle mass

[Medicxi @medicxi]

Differentiated pharmacology too compelling for @Medicxi partner Nick Williams to pass up when he led our Series A investment <2 years ago